Bedrijfsoverzicht
Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical entity focused on the development and commercialization of therapeutic products designed to address immuno-inflammatory and rare diseases within the United States market. The corporation operates primarily through its Pharmaceutical and Biotechnology segments, leveraging its expertise in clinical-stage research to bring specialized treatments to patients with complex medical conditions. Operating in the broader Healthcare sector and specifically within the Biotechnology industry, the company represents a niche player targeting high-need therapeutic areas that often require significant regulatory and scientific advancement. As of the latest reported data, the company maintains a total market capitalization of $15.37M, generates $319,714 in annual revenue, and employs a workforce of 9 individuals. These financial figures indicate that Vyome Holdings is a micro-cap entity with a relatively small revenue base, suggesting it is in an early-stage development phase where capital allocation is heavily weighted toward research, development, and clinical trial expenses rather than large-scale commercial operations or established market share dominance.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $319,714, yet it posted a net income of $-10,262,007 and an EBITDA of $-2,735,052, revealing a substantial disparity between top-line generation and profitability driven by high operating costs associated with clinical-stage biotechnology development. Despite the negative net income and EBITDA, the company reported a free cash flow of $5.11M and holds a cash balance of $4.98M, which provides a critical buffer for operational continuity and funding of ongoing research initiatives without immediate external capital raising. The gross margin stands at 68.4%, indicating that the cost of goods sold relative to revenue is manageable for a clinical-stage firm, whereas the operating margin of -3707.4% and profit margin of 0.0% highlight the extreme inefficiency or high fixed cost burden typical of companies with minimal revenue but significant research expenditures. On the liability side, Vyome Holdings carries $31,258 in debt against a cash position of $4.98M, resulting in a debt-to-equity ratio of 0.83, which suggests a balance sheet that is largely un-leveraged by traditional interest-bearing debt despite the negative earnings. The current ratio is 1.99, indicating that the company possesses nearly double the current assets compared to current liabilities, which points to strong short-term liquidity and the ability to meet immediate financial obligations. Furthermore, the return on equity is listed as N/A due to the specific accounting treatment of net income against equity in this stage, while the return on assets is -43.6%, reflecting that the asset base is currently generating negative returns due to the heavy investment in clinical-stage assets and the lack of profitable operations.
Waarderingsbeoordeling
The trailing P/E ratio is N/A and the forward P/E is also N/A, reflecting the fact that the company is currently unprofitable and thus cannot be valued using traditional earnings multiples that imply a future earnings trajectory based on historical performance. Instead, investors look to the price-to-book ratio of 5.30, which suggests the market values the company at more than five times its book value, potentially pricing in future clinical trial successes or the intrinsic value of intellectual property that is not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 48.08 and an EV/EBITDA of -4.29 further illustrate that the stock is being priced on revenue multiples or speculative growth potential rather than current earnings power or cash flow generation. The stock price has historically traded between a 52-week high of $56.40 and a 52-week low of $1.75, a range that demonstrates extreme volatility often seen in clinical-stage biotechs, though the current trading price sits within this historical window without specific directional bias. The beta value is N/A, meaning that standard measures of volatility relative to the broader market are not applicable or reported for this specific ticker in the available data.
Growth & Income
Revenue growth year-over-year is -40.5%, while earnings growth year-over-year is N/A, indicating that the company is currently experiencing a contraction in sales or a decline in the scale of its operations relative to the prior period. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, which implies that all available earnings, if any, or the company's cash reserves are being retained to fund its research and development pipeline rather than being distributed to shareholders. The lack of a dividend payout is consistent with the profile of a clinical-stage biotechnology company that must reinvest its resources into advancing product candidates like VT-1953 through clinical trials before generating sustainable commercial income. The overall growth and income profile of Vyome Holdings is characterized by significant revenue contraction and a complete absence of dividend income, positioning the stock as a pure speculative play on future clinical outcomes rather than a vehicle for current income generation or steady revenue expansion.